Đang chuẩn bị liên kết để tải về tài liệu:
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Nivolumab is an immune checkpoint inhibitor specific to the programmed death 1 (PD-1) receptor. Nivolumab has shown clinical responses in many malignancies. Although immune-related adverse events (irAEs) associated with nivolumab are largely tolerable, severe irAEs have occurred in some patients. | Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients Potential role of Th1-dominant immune response in immune-related adverse events Two case reports

TÀI LIỆU LIÊN QUAN

The development of magnetic tunnel junction fabrication techniques

WOMEN’S HEALTH IN CRISES - LEADING OFF

GLOBAL FOREST RESOURCES ASSESSMENT 2010: COUNTRY REPORT KENYA

A severe presentation of chronic noninfectious osteomyelitis associated with ulcerative colitis: A case report

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: Potential role of Th1-dominant immune response in immune-related adverse events: Two case reports

VIRAL GENE THERAPY

SKELETAL MUSCLE – FROM MYOGENESIS TO CLINICAL RELATIONS

TRADE AND ENVIRONMENT REVIEW 2006

Creating A Healthy Environment: The Impact of the Built Environment on Public Health

National Survey of Substance Abuse Treatment Services (N-SSATS): 2002
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.